399 related articles for article (PubMed ID: 30647164)
1. Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis/dermatomyositis-associated Interstitial Lung Disease: A Propensity Score-matched Analysis.
Hozumi H; Fujisawa T; Nakashima R; Yasui H; Suzuki Y; Kono M; Karayama M; Furuhashi K; Enomoto N; Inui N; Nakamura Y; Mimori T; Suda T
J Rheumatol; 2019 May; 46(5):509-517. PubMed ID: 30647164
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study.
Hozumi H; Enomoto N; Kono M; Fujisawa T; Inui N; Nakamura Y; Sumikawa H; Johkoh T; Nakashima R; Imura Y; Mimori T; Suda T
PLoS One; 2015; 10(3):e0120313. PubMed ID: 25789468
[TBL] [Abstract][Full Text] [Related]
4. Combination of Prednisolone and Calcineurin Inhibitors Prevents Lung Function Decline in Patients with Anti-aminoacyl-tRNA Synthetase Antibody-Positive Polymyositis/Dermatomyositis.
Yorishima Y; Tominaga M; Fujimoto K; Nagata S; Sumi A; Chikasue T; Okamoto M; Kaieda S; Matama G; Zaizen Y; Obara H; Kakuma T; Ida H; Kawayama T; Hoshino T
Kurume Med J; 2023 Nov; 69(1.2):19-30. PubMed ID: 37544752
[TBL] [Abstract][Full Text] [Related]
5. Comparison of cytokine profiles between anti-ARS antibody-positive interstitial lung diseases and those with anti-MDA-5 antibodies.
Asakawa K; Yoshizawa K; Aoki A; Kimura Y; Tanaka T; Ohashi K; Hayashi M; Kikuchi T; Sato S; Takada T
Clin Rheumatol; 2020 Jul; 39(7):2171-2178. PubMed ID: 32056068
[TBL] [Abstract][Full Text] [Related]
6. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics of patients with anti-aminoacyl-tRNA synthetase antibody positive idiopathic interstitial pneumonia.
Yura H; Sakamoto N; Satoh M; Ishimoto H; Hanaka T; Ito C; Hasegawa T; Tanaka S; Miyamura T; Nakashima S; Hara A; Kakugawa T; Oda K; Kido T; Obase Y; Ishimatsu Y; Yatera K; Kawakami A; Mukae H
Respir Med; 2017 Nov; 132():189-194. PubMed ID: 29229096
[TBL] [Abstract][Full Text] [Related]
8. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome.
Hamaguchi Y; Fujimoto M; Matsushita T; Kaji K; Komura K; Hasegawa M; Kodera M; Muroi E; Fujikawa K; Seishima M; Yamada H; Yamada R; Sato S; Takehara K; Kuwana M
PLoS One; 2013; 8(4):e60442. PubMed ID: 23573256
[TBL] [Abstract][Full Text] [Related]
9. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
Yoshida N; Okamoto M; Kaieda S; Fujimoto K; Ebata T; Tajiri M; Nakamura M; Tominaga M; Wakasugi D; Kawayama T; Kuwana M; Mimori T; Ida H; Hoshino T
Respir Investig; 2017 Jan; 55(1):24-32. PubMed ID: 28012490
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics of dermatomyosits/polymyositis associated interstitial lung disease according to the autoantibody.
Kishaba T; McGill R; Nei Y; Ibuki S; Momose M; Nishiyama K; Nagano H; Yamashiro S
J Med Invest; 2018; 65(3.4):251-257. PubMed ID: 30282869
[TBL] [Abstract][Full Text] [Related]
11. Effective Use of Calcineurin Inhibitor in Combination Therapy for Interstitial Lung Disease in Patients With Dermatomyositis and Polymyositis.
Shimojima Y; Ishii W; Matsuda M; Kishida D; Ikeda SI
J Clin Rheumatol; 2017 Mar; 23(2):87-93. PubMed ID: 28225510
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for the recurrence of interstitial lung disease in patients with polymyositis and dermatomyositis: a retrospective cohort study.
Nakazawa M; Kaneko Y; Takeuchi T
Clin Rheumatol; 2018 Mar; 37(3):765-771. PubMed ID: 28975463
[TBL] [Abstract][Full Text] [Related]
13. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease.
Gono T; Kaneko H; Kawaguchi Y; Hanaoka M; Kataoka S; Kuwana M; Takagi K; Ichida H; Katsumata Y; Ota Y; Kawasumi H; Yamanaka H
Rheumatology (Oxford); 2014 Dec; 53(12):2196-203. PubMed ID: 24970922
[TBL] [Abstract][Full Text] [Related]
14. Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis/dermatomyositis: a single-arm clinical trial.
Takada K; Katada Y; Ito S; Hayashi T; Kishi J; Itoh K; Yamashita H; Hirakata M; Kawahata K; Kawakami A; Watanabe N; Atsumi T; Takasaki Y; Miyasaka N
Rheumatology (Oxford); 2020 May; 59(5):1084-1093. PubMed ID: 31539061
[TBL] [Abstract][Full Text] [Related]
15. Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China.
Zhan X; Yan W; Wang Y; Li Q; Shi X; Gao Y; Ye Q
BMC Pulm Med; 2021 Feb; 21(1):57. PubMed ID: 33579248
[TBL] [Abstract][Full Text] [Related]
16. Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies.
Chen F; Li S; Wang T; Shi J; Wang G
Am J Med Sci; 2018 Jan; 355(1):48-53. PubMed ID: 29289262
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis.
Matsushita T; Hasegawa M; Fujimoto M; Hamaguchi Y; Komura K; Hirano T; Horikawa M; Kondo M; Orito H; Kaji K; Saito Y; Matsushita Y; Kawara S; Yasui M; Seishima M; Ozaki S; Kuwana M; Ogawa F; Sato S; Takehara K
J Rheumatol; 2007 May; 34(5):1012-8. PubMed ID: 17309126
[TBL] [Abstract][Full Text] [Related]
18. Two cases with autoantibodies to small ubiquitin-like modifier activating enzyme: A potential unique subset of dermatomyositis-associated interstitial lung disease.
Gono T; Tanino Y; Nishikawa A; Kawamata T; Hirai K; Okazaki Y; Shibata Y; Kuwana M
Int J Rheum Dis; 2019 Aug; 22(8):1582-1586. PubMed ID: 31050194
[TBL] [Abstract][Full Text] [Related]
19. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
[TBL] [Abstract][Full Text] [Related]
20. Dermatomyositis with Rapidly Progressive Interstitial Lung Disease Treated with Rituximab: A Report of 3 Cases in Japan.
Tokunaga K; Hagino N
Intern Med; 2017; 56(11):1399-1403. PubMed ID: 28566605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
